Diamyd discussing potential consolidation of Phase III trials
Diamyd Medical is conducting two clinical Phase III trials of the Diamyd® diabetes vaccine in children and adolescents with recent onset type 1 diabetes: one in the US and one in nine European countries. In parallel the company is discussing with the regulatory agencies about combining the two trials into one global trial.In addition to reducing costs, combining the trials would mean that countries with the fastest rate of patient recruitment could contribute to the greatest extent. The Phase III program encompasses ten countries: Italy, Finland, France, the Netherlands, Slovenia, Spain,